Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]

Cellular and Molecular Neurobiology

Volumn 21, Issue 6, 2001, Pages 555-573

  Youdim, Moussa B H ^a   Weinstock, Marta ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Acetylcholine; Alzheimer's disease; Apoptosis; APP; Bcl 2; Depressive illness; Dopamine; monoamine oxidase acetylcholinestrate; Neuroprotection; Parkinson's disease; PKC; Rasagiline; TV3326

Indexed keywords

(N PROPARGYL AMINOINDAN 5 YL)ETHYLMETHYLCARBAMATE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENINE NUCLEOTIDE TRANSLOCASE; ALPHA SECRETASE; AMYLOID PRECURSOR PROTEIN; ANTIALZHEIMER AGENT; BENZODIAZEPINE RECEPTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEXOKINASE; LADOSTIGIL; LEVODOPA; LINSIDOMINE; MITOGEN ACTIVATED PROTEIN KINASE; MONOAMINE OXIDASE B INHIBITOR; N METHYL SALSOLINOL; NEUROPROTECTIVE AGENT; NEUROTOXIN; OXIDOPAMINE; PORIN; PROTEIN BCL 2; PROTEIN KINASE C; RASAGILINE; RIVASTIGMINE; SALSOLINOL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; BRAIN CORTEX; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG BINDING; ENANTIOMER; ENZYME ACTIVATION; ENZYME REGULATION; FORCED SWIMMING TEST; HIPPOCAMPUS; HUMAN; HUMAN CELL; LONG TERM CARE; LONG TERM EXPOSURE; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; MOLECULAR DYNAMICS; NEUROBLASTOMA CELL; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN INDUCTION; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOPTOSIS; BRAIN; CHOLINESTERASE INHIBITORS; HUMANS; INDANS; NEURONS; NEUROPROTECTIVE AGENTS;

GYMNOMYZA SAMOENSIS;

EID: 0035568344     PISSN: 02724340     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015131516649     Document Type: Review

References (71)

1. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentated PC12 cells against oxygen-glucose deprivation
2. Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells
3. Effect of streptozotocin on glutathione and lipid peroxide levels in various tissues of rats
4. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor
5. Protein phosphorylation inhibits production of Alzheimer amyloid beta/A4 peptide
6. Reduced apoptosis after nerve growth factor and serum withdrawal: Conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer
7. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat
8. Thrombin receptor activation induces secretion and on amyloidogenic processing of amyloid beta-protein precursor
9. Gene expression and behavioral profile of different types of anti and nonantidepressant drugs
10. Intra-cerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats
11. Drug choice in depression. Selective serotonin reuptake inhibitors or tricyclic antidepressants?
12. Cleavage of amyloid beta peptide during constitutive processing of its precursor
13. Selegiline in the treatment of Alzheimer's disease: A long-term randomized placebocontrolled trial. Czech and Slovak Senile
14. Pharmacology and neuroprotective properties of rasagiline
15. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B
16. Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat
17. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey
18. Pharmacology of rasagiline (N-propargyl-1R-aminoindan)
19. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor
20. Cholinesterase inhibitors for Alzheimer's disease therapy: From tacrine to future application
21. The effect of cholinesterase inhibitors on the ecretion of APPS from rat brain cortex
22. Second and third generation cholinesterase inhibitors: From preclinical studies to clinical efficacy
23. The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture
24. Effects of traumatic brain injury on the cholinergic system in the rat
25. Bcl-2 over-expression and activation of protein kinase C suppress the trail-induced apoptosis in Jurkat T cells
26. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B
27. Neuroprotective effect of rasagiline, a selective MAO-B inhibitor, against closed head injury in the mouse
28. Selective acetylenic "suicide" and reversible inhibitors of monoamine oxidase types A and B
29. Neuropathological aspects of brain edema
30. Selegiline completely restores choline acetyltransferase activity deficits in simian immunodeficiency infection
31. Cholinesterase inhibitors: A therapeutic strategy in Alzheimer disease
32. Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures
33. Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo
34. Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors
35. Resistance to induced apoptosis in the human neuroblastoma cell line SK-N-SH in relation to neuronal differentiation. Role of Bcl-2 protein family
36. Neurotoxins induce apoptosis in dopamine neurons: Protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022
37. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol
38. Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline
39. Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022
40. Regulation of amyloid precursor protein cleavage
41. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex
42. Anti-apoptotic function of L-(-)deprenyl (Selegiline) and related compounds
43. The prevalence of depression in Alzheimer's disease and vascular dementia in a population sample
44. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors
45. Receptor-coupled amyloid precursor protein processing
46. Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion
47. Possible neurotransmitter basis of behavioral changes in Alzheimer's disease
48. Reversible and irreversible acetylcholinesterase inhibitors cause changes in neuronal amyloid precursor protein processing and protein kinase C level in vitro
49. A Controlled Clinical Trial of Rasagiline in Early Parkinson's Disease
50. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa
51. Rationalizing a pharmacological intervention on the amyloid precursor protein metabolism
52. Treatment with metrifonate promotes soluble amyloid precursor protein release from SH-SY5Y neuroblastoma cells, in Alzheirmer's Disease and Related Disorders
53. Neuroprotection and neurorescue of nigrostriatal dopamine neurons in MPTP treated mice by rasagiline and TV3326
54. Controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease
55. Evidence that betaamyloid protein in Alzheimer's disease is not derived by normal processing
56. Rapid stimulation of amyloid precursor protein release by epidermal growth factor: Role of protein kinase C
57. Direct measurement of hydroxyl radicals, lipid peroxidation, and blood-brain barrier disruption following unilateral cortical impact head injury in the rat
58. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat
59. Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders
60. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat
61. (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: Highly selective and potent inhibitors of monoamine oxidase B
62. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis
63. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: Time course and modification by (-)-deprenyl
64. Selectivity of cholinesterase inhibition: Clinical implications for the treatment of Alzheimer's disease
65. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease
66. Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities
67. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs
68. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain
69. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B
70. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition incell culture and in vivo
71. Novel neuroprotective anti-Alzheimer drug with antidepressant activity derived from the anti-Parkinson drug, rasagiline